LYiClustersiPD-L1 could deliver LY2157299 to PSCs and release PAMAM/siPD-L1 to penetrate into tumors and target tumor cells. On synergistic therapy of both, enhanced CD8+ T cell infiltration and cytotoxicity were expected.